Herati, Ramin Sedaghat http://orcid.org/0000-0003-2613-4050
Knorr, David A. http://orcid.org/0000-0002-0766-8914
Vella, Laura A. http://orcid.org/0000-0002-8917-4845
Silva, Luisa Victoria
Chilukuri, Lakshmi
Apostolidis, Sokratis A. http://orcid.org/0000-0002-0224-0097
Huang, Alexander C. http://orcid.org/0000-0002-0099-0492
Muselman, Alexander http://orcid.org/0000-0002-5685-2646
Manne, Sasikanth
Kuthuru, Oliva
Staupe, Ryan P.
Adamski, Sharon A.
Kannan, Senthil
Kurupati, Raj K.
Ertl, Hildegund C. J.
Wong, Jeffrey L.
Bournazos, Stylianos http://orcid.org/0000-0001-5466-5620
McGettigan, Suzanne
Schuchter, Lynn M.
Kotecha, Ritesh R.
Funt, Samuel A. http://orcid.org/0000-0002-7235-6319
Voss, Martin H. http://orcid.org/0000-0003-0551-5807
Motzer, Robert J. http://orcid.org/0000-0001-6925-2327
Lee, Chung-Han http://orcid.org/0000-0001-5511-0635
Bajorin, Dean F. http://orcid.org/0000-0003-4001-7088
Mitchell, Tara C. http://orcid.org/0000-0002-8186-7284
Ravetch, Jeffrey V. http://orcid.org/0000-0003-2024-9041
Wherry, E. John http://orcid.org/0000-0003-0477-1956
Article History
Received: 23 June 2021
Accepted: 20 June 2022
First Online: 28 July 2022
Competing interests
: E.J.W. is an advisor for Merck, Marengo, Janssen, Related Sciences, Synthekine and Surface Oncology. E.J.W. is a founder of Surface Oncology, Danger Bio and Arsenal Biosciences. E.J.W. has a patent on the PD-1 pathway. R.S.H.’s spouse is an employee of Merck but was not involved in the studies. A.C.H. is a consultant for Immunai and received research funding from BMS. T.C.M. has had advisory roles with Merck, Bristol-Myers Squibb, OncoSec, GigaGen and Instil Bio. D.F.B. reports consulting fees from Bristol-Myers Squibb, Merck, Genentech‐Roche, AstraZeneca and Pfizer, and institutional research support from Merck, Genentech‐Roche, AstraZeneca, Novartis and Bristol‐Myers Squibb. S.A.F. reports consulting fees from Merck, institutional research support from AstraZeneca and Genentech/Roche, and has stock and other ownership interest in Urogen, Allogene Therapeutics, Neogene Therapeutics, Kronos Bio, Iconovir and Vida Ventures. C.-H.L. served in a consultancy or advisory role to Amgen, Bristol-Myer Squibb, Exelixis, Merck, Pfizer, EMD Serono and Eisai, and also received research funding from Bristol-Myers Squibb, Calithera, Eisai, Exelixis, Eli Lilly, Merck and Pfizer. R.J.M. served in a consultancy or advisory role for Pfizer, Novartis, Merck, Genentech/Roche, Eisai and Exelixis, and received research funding from Bristol-Myers Squibb, Merck, Pfizer, Genentech/Roche, Eisai, Exelixis and Novartis outside of the submitted work. M.H.V. had the following consulting or advisory roles: Alexion Pharmaceuticals, Calithera Biosciences, Exelixis, GlaxoSmithKline, Natera, Novartis, Pfizer; research funding: Bristol-Myers Squibb, Genentech/Roche, Pfizer; personal fees: Novartis, Takeda; travel fees: Novartis, Takeda, Eisai, AstraZeneca; honoraria: Novartis, outside of the submitted work. The remaining authors declare no competing interests.
Free to read: This content has been made available to all.